Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 20;12(1):1746520. doi: 10.1080/19420862.2020.1746520

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 9. — Anti-muIL-36 R mAb (M616) biodistribution in C57BL/6 mouse plotted as tissue:blood ratios over 120 h. (Top left) ¹²⁵I-M616 (0.3 mg/kg) PK in tissue highlights kidney and skin as sites of tissue retention/accumulation, while ¹²⁵I-M616 dosed in combination with 9.7 mg/kg unlabeled M616 (top right) confirms specific uptake in these organs. (Bottom left) ¹¹¹In-M616 was utilized as a more sensitive tracer to identify sites of M616 catabolism based on residualization properties of the ¹¹¹In probe in tissue. Here, the kidney, liver, spleen, and skin are implicated as possible sites of IL-36 R-mediated uptake clearance. (bottom right) Excess cold M616 significantly mitigates tissue catabolism of ¹¹¹In-M616, again indicating specific uptake/catabolism in these organs.